Legend clinical hold raises questions about CAR Ts for T cell cancers

The application of CAR T cell therapies to T cell lymphomas hit a roadblock on Tuesday when Legend announced that FDA had placed a clinical hold on its Phase I trial of LB1901. It’s not clear, however, if the event that triggered the hold was wholly unexpected or if it will read through to the other T cell targets of CAR T therapies.

Legend Biotech Corp. (NASDAQ:LEGN) reported that the hold was placed on Feb. 11 after the only patient dosed in the study had a low CD4⁺ T cell count in peripheral blood...